Hepatitis

Five things for pharma marketers to know: Tuesday, May 5

Five things for pharma marketers to know: Tuesday, May 5

By

Worldwide spending on cancer medications hit $100 billion last year; Bayer adds an anticoagulant to its pipeline for $100 million; GlaxoSmithKline has a new chairman

Five things for pharma marketers to know: Friday, April 24

Five things for pharma marketers to know: Friday, April 24

By

An AbbVie hep.-C drug nabbed priority review; Merck's hep.-C drug matches efficacy of Harvoni; Mylan increased its bid to buy Perrigo

Mylan's generic Sovaldi launches in India

The hepatitis-C drug is being sold under the name MyHep.

Medicare shelled out more than $4.7 billion on hep C last year

Key contributors to the total: Sovaldi, Harvoni and Olysio

Report: US drug spending jumped 13% in 2014

Report: US drug spending jumped 13% in 2014

By

PBM Express Scripts said last year's trends reflect a major shift in how the pharmaceutical industry does business and that generics are not the bargain they once were.

Five things for pharma marketers to know: Tuesday, March 10

Five things for pharma marketers to know: Tuesday, March 10

By

HCV drugs and other specialty medications drove a 13% increase in last year's prescription spending, the CBO overestimated just how much healthcare reform would cost, and an FDA panel voted 17-0 in favor of Kythera's drug that can reduce double chins.

Five things for pharma marketers to know: Tuesday March 3

Five things for pharma marketers to know: Tuesday March 3

By

NICE greenlights Harvoni for Britain's national formulary, Pacira received a CRL instead of an expanded indication and Novo's latest diabetes outreach focuses on patients instead of drug brands.

Specialty medications have PBMs on edge

Specialty medications have PBMs on edge

By

CVS health execs write that cost of long-term specialty medications, not short-timers like Sovaldi, are a major worry.

Five things for pharma marketers to know: Friday, February 13

Five things for pharma marketers to know: Friday, February 13

By

FDA approves Eisai's thryoid cancer drug two months early, Gilead and Germany agree to a Sovaldi price cut, and Valeant looks set to make a bid for Salix.

Five things for pharma marketers to know: Wednesday, February 11

Five things for pharma marketers to know: Wednesday, February 11

By

BMS loses breakthrough therapy status, Gilead's pricing comes under fire in Europe, and pharma fights Italy's off-label Avastin use.

FDA rescinds Merck HCV therapy's Breakthrough Designation

FDA rescinds Merck HCV therapy's Breakthrough Designation

By

The drugmaker announced in its earnings call Wednesday that the FDA has rescinded the company's Breakthrough Therapy designation, which could delay Merck's HCV doublet therapy launch from early to mid-2016.

Five things for pharma marketers to know: Thursday, January 29

Five things for pharma marketers to know: Thursday, January 29

By

Former FDA chief tells court J&J knew of Risperdal risk, pay-for-delay deals get new court criteria, lawmakers may declare pharmacists healthcare providers.

Merck to end US Victrelis distribution this year

The hepatitis C medication will be on the US dustheap, but Merck expects to file a new drug with the FDA later this year.

J&J Q4 sales slip, but year finishes up 4.2%

J&J Q4 sales slip, but year finishes up 4.2%

By

Despite growth, some disappointment lurks in the numbers -- possibly for hepatitis C medication Olysio.

AbbVie to discount HCV drugs for state HIV programs

A deal struck by the drugmaker calls for state HIV programs to access its HCV combo, Viekira Pak, at a significant discount.

J&J offers government payer hep. C guarantee

The drugmaker is offering Scotland's NHS a money-back guarantee for Olysio patients.

Hep. C medication boosts J&J earnings

Hep. C medication boosts J&J earnings

By

Hepatitis C medication Olysio contributed to the the 18% bump in Johnson & Johnson's third-quarter sales, but Gilead's new drug may diminish J&J's potential.

Hep. C medication boosts J&J earnings

Hep. C medication boosts J&J earnings

By

Hepatitis C medication Olysio contributed to the the 18% bump in Johnson & Johnson's third-quarter sales, but Gilead's new drug may diminish J&J's potential.

Harvoni's price is shaping the field

The regimen's anticipated average price of $80,000 is expected to determine how competitors stay competitive.

Harvoni's price is shaping the field

The regimen's anticipated average price of $80,000 is expected to determine how competitors stay competitive.

Five things for pharma marketers to know: Friday, September 19

Five things for pharma marketers to know: Friday, September 19

By

Lilly's weekly GLP-1 shot is approved, BI expands its lung-cancer portfolio, GSK's China investigation closes, NY proposed Sovaldi triage and India imposed price limits on 36 new medicines.

Rate of Sovaldi non-adherence points to need for patient support

Rate of Sovaldi non-adherence points to need for patient support

By

A mélange of new treatments awaiting approval and a lack of patient support are driving down drug utilization for Gilead's HCV blockbuster, according to a new study.

Drug spend will continue to rise through 2023

Drug spend will continue to rise through 2023

By

The numbers folks at the Centers for Medicare and Medicaid Services anticipate sluggish growth in US healthcare spend, but prescriptions look ready to take off.

Roche has no rights to Sovaldi, panel rules

Despite a collaboration with original Sovaldi owner Pharmasset in 2004, a panel ruled Roche has no rights to HCV treatment Sovaldi.

 Five things for pharma marketers to know: Friday, August 15

Five things for pharma marketers to know: Friday, August 15

By

UK drug-cost watchdog backs Sovaldi, Achillion touts HCV interim results, Avastin's latest cancer indication, Ebola outbreak worsens, COPD drug gets panel nod, and study links quick reviews and black-box warnings.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on horizon

By

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

J&J logs $19.5B in Q2 sales

J&J logs $19.5B in Q2 sales

By

Hepatitis C medication Olysio was a star, but the company cautions competition is coming.

Vertex to submit CF drug combo to FDA this year

Vertex to submit CF drug combo to FDA this year

By

Phase III results showing improved lung function among cystic fibrosis patients using a combination of Kalydeco and lumacaftor means drugmaker Vertex is filing the two-part drug for FDA approval during the fourth quarter.

BI calls it quits in hep. C

BI says there is no unmet need for faldaprevir.

FDA labels AbbVie hep C drug Breakthrough

The all-oral genotype 1 medication got the Breakthrough Therapy designation Friday.


Email Newsletters


Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.